Taxis Pharmaceuticals
TAXIS Pharmaceuticals Inc., a biopharmaceutical firm specializing in developing drugs for resistant bacterial pathogens.
TAXIS Pharmaceuticals Inc., a biopharmaceutical firm specializing in developing drugs for resistant bacterial pathogens.
TAXIS Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative therapies to combat antimicrobial resistance. The company focuses on treating multidrug-resistant bacterial pathogens by targeting the root causes of bacterial survival. TAXIS Pharmaceuticals employs a unique approach that goes beyond traditional methods, aiming to dismantle cellular infrastructure and disrupt mechanisms that enable antimicrobial resistance. Their mission is to envision a world where antimicrobial resistance is effectively tackled.
TAXIS Pharmaceuticals has made significant strides in the field of drug discovery, positioning itself as a key player in the fight against antimicrobial resistance. By focusing on novel therapeutic strategies, the company has contributed to advancing the understanding and treatment of resistant bacterial infections. Their pioneering work has garnered attention within the biopharmaceutical industry, highlighting their impact on public health and the potential to transform the landscape of infectious disease treatment.
Companies similar to Taxis Pharmaceuticals include X-Biotix Therapeutics, Recida Therapeutics, Biolytx Pharmaceuticals and Endolytix.
Taxis Pharmaceuticals was founded in 2009.
Taxis Pharmaceuticals' headquarters is located in Monmouth Junction, NJ, US.
Taxis Pharmaceuticals' most recent funding round was for $3.2M (USD) in September 2019.
As of Sep 1, 2019, Taxis Pharmaceuticals has disclosed funding of $6.2M (USD). Undisclosed round amounts are excluded.
Taxis Pharmaceuticals has 28 employees as of Feb 5, 2024.
Endolytix
